

## Anti-CTLA-8/IL-17a Antibody (Ixekezumab)

### Introduction

Ixekezumab is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD < 3 pM). Ixekezumab directly blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekezumab is being studied in moderate to severe plaque psoriasis.

### Product parameters

Alternative Names	Taltz, LY2439821
Target Accession	Q16552
Target	CTLA-8 / IL-17a
CAS number	1143503-69-8
Molecular Weight	146.44 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

